These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 39093344)

  • 1. Antibody-drug conjugates for breast cancer: a bibliometric study and clinical trial analysis.
    Xing M; Li Z; Cui Y; He M; Xing Y; Yang L; Liu Z; Luo L; Wang H; Guo R
    Discov Oncol; 2024 Aug; 15(1):329. PubMed ID: 39093344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment.
    Gao X; Bu T; Wang W; Xu Y
    Breast Cancer (Dove Med Press); 2024; 16():621-630. PubMed ID: 39310781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis.
    Yao P; Zhang Y; Zhang S; Wei X; Liu Y; Du C; Hu M; Feng C; Li J; Zhao F; Li C; Li Z; Du L
    Front Oncol; 2022; 12():1039882. PubMed ID: 36686767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
    Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bibliometric study of immunotherapy for hepatocellular carcinoma.
    Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
    Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
    Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
    Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study.
    Qi X; Li Y; Liu W; Wang Y; Chen Z; Lin L
    Front Pharmacol; 2022; 13():921385. PubMed ID: 35795565
    [No Abstract]   [Full Text] [Related]  

  • 11. A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus.
    Zhang R; Jiang Q; Zhuang Z; Zeng H; Li Y
    Front Immunol; 2024; 15():1452303. PubMed ID: 39188717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancements and trends in exosome research in lung cancer from a bibliometric analysis (2004-2023).
    Zhong W; Zhao X; Zhang X; Xu Y; Liu M; Yang X; Jiang Y; Shen X
    Front Oncol; 2024; 14():1358101. PubMed ID: 38690166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.
    Su Y; Ruan Z; Wang R; Hao S; Tang Y; Huang X; Gao T; Li Z; Chang T
    Front Immunol; 2022; 13():998217. PubMed ID: 36248874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bibliometric analysis of HER2-positive breast cancer: 1987-2024.
    Ali-Thompson S; Daly GR; Dowling GP; Kilkenny C; Cox L; McGrath J; AlRawashdeh MM; Naidoo S; Power C; Hill ADK
    Front Oncol; 2024; 14():1355353. PubMed ID: 38769947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
    Shih CH; Lin YH; Luo HL; Sung WW
    Front Pharmacol; 2024; 15():1326296. PubMed ID: 38572425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
    Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
    Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bibliometric and visualized analysis of ultrasound combined with microbubble therapy technology from 2009 to 2023.
    Tu B; Li Y; Wen W; Liu J
    Front Pharmacol; 2024; 15():1418142. PubMed ID: 39119614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.